Next-Generation Sequencing (NGS) Center of Excellence
Avance Biosciences’ NGS Center of Excellence is dedicated to delivering high-quality, CGMP/GLP-compliant sequencing solutions to support every stage of biopharmaceutical development, from discovery through clinical validation and testing.
Our mission is to unite advanced sequencing expertise to maximize efficiency, foster innovation, and provide cutting-edge support for drug development and manufacturing, ensuring we stay agile in a rapidly evolving industry.
Next-Generation Sequencing (NGS) Center of Excellence
Avance Biosciences’ NGS Center of Excellence is dedicated to delivering high-quality, CGMP/GLP-compliant sequencing solutions to support every stage of biopharmaceutical development, from discovery through clinical validation and testing.
Our mission is to unite advanced sequencing expertise to maximize efficiency, foster innovation, and provide cutting-edge support for drug development and manufacturing, ensuring we stay agile in a rapidly evolving industry.
Next-Gen and Third-Gen Sequencing Platforms
Equipped with leading platforms, including Illumina, PacBio, Oxford Nanopore, Element AVITI™, and 10x Genomics, we offer unmatched expertise in vector characterization, transgene expression, CRISPR analysis, biodistribution, and release testing. Our integrated approach ensures precise, reliable data to accelerate regulatory submissions, enhance product safety, and advance innovative therapies from research through commercialization.
Sequencing Services
DNA Sequencing
RNA Sequencing
Epigenome
Whole Genome Sequencing (WGS)
Poly(A) / Transcriptomics (RNA-seq)
Whole Genome Bisulfite
Exome Sequencing
Total RNA Sequencing
Reduced Representation Bisulfite
Targeted / PCR-based Sequencing
Single-Cell Gene Expression and Immune Profiling
Chromatin Immunoprecipitation (ChIP-seq)
Metagenomic Sequencing
Metatranscriptome Sequencing
RNA Immunoprecipitation
Plasmid/Vector Sequencing
Gene Therapy Vector Sequencing
Enzymatic Methyl
Digital Southern
Isoform Sequencing
Assay for Transposase-Accessible Chromatic (ATAC-Seq)
Integration Site Analysis
Long ncRNA Sequencing
Adventitious Agent Testing
mRNA-Based Therapy
Technical Information
Next-generation sequencing (NGS) technologies are transforming regulated drug development by enabling high-resolution analysis for applications such as gene editing, adventitious agent detection, and sequence confirmation. However, integrating NGS into GMP and GLP workflows introduces significant challenges related to data integrity and compliance with 21 CFR Part 11. These regulations require strict controls over electronic records...
This guide provides an in-depth look at GUIDE-Seq/iGuide, a key technique for assessing CRISPR-Cas9 on- and off-target effects in gene and cell therapy development. It explains how the method informs the selection of gRNAs, nucleases, and CRISPR conditions to maximize specificity and safety. Readers will also gain insights into the full workflow, from Cas9 cleavage to NGS analysis, supported by Avance Biosciences’ expertise as a licensed GUIDE-Seq service provider...
Explore the power of Next Generation Sequencing (NGS) for biologics development support with our latest whitepaper. Avance Biosciences is at the forefront of NGS testing, offering tailored solutions to support drug development initiatives and GMP manufacturing activities. Delve into real-world case studies, including CRISPR indel amplicon sequencing and insertion site studies, showcasing our expertise in assay development and validation...
Next- and third-generation sequencing are vital for GMP, GLP, and clinical applications, but data integrity challenges and 21 CFR Part 11 compliance require secure instruments, validated workflows, and robust audit trails...
Genome editing offers unprecedented precision, but off-target effects remain a key safety concern. GUIDE-Seq provides a high-throughput, genome-wide method to map CRISPR-Cas activity in living cells, enabling researchers to assess specificity and ensure safer gene-editing therapies...
